Front. Antibiot. Frontiers in Antibiotics Front. Antibiot. 2813-2467 Frontiers Media S.A. 10.3389/frabi.2025.1748877 Correction Correction: Inclusion of patient-centered, non-microbiological endpoints and biomarkers in tuberculosis drug trials DiNardoAndrew R. 1 2 * Writing – original draft Writing – review & editing SabiitiWilbert 3 GillespieStephen H. 3 GeorghiouSophia B. 4 HeinrichNorbert 5 6 HittelNorbert 7 TaghlabiSami 2 LonglaxDanna Carrero 2 KohliMikashmi 4 PanznerUrsula 5 6 MusiaCollins 8 LangeChristoph 2 8 9 10 VasiliuAnca 2 8 9 ArtsRob J. W. 1 MandalakasAnna M. 2 8 9 RuhwaldMorten 4 StuyverLieven J. 11 van CrevelReinout 3 12 Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands The Global Tuberculosis Program, Texas Children’s Hospital, Department of Pediatrics, Baylor College of Medicine, Houston, TX, United States Division of Infectious Disease and Global Health, University of St Andrews, St Andrews, United Kingdom FIND, Geneva, Switzerland Division of Infectious Diseases and Tropical Medicine, LMU University Hospital, Munich, Germany German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany Otsuka Novel Products GmbH, Munich, Germany German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany Respiratory Medicine & International Health, University of Lübeck, Lübeck, Germany Janssen Global Public Health R&D, Janssen Pharmaceutica NV, Beerse, Belgium Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom Correspondence: Andrew R. DiNardo, andrew.dinardo@bcm.edu 02 03 2026 2025 4 1748877 19 11 2025 10 12 2025 Copyright © 2026 DiNardo, Sabiiti, Gillespie, Georghiou, Heinrich, Hittel, Taghlabi, Longlax, Kohli, Panzner, Musia, Lange, Vasiliu, Arts, Mandalakas, Ruhwald, Stuyver and van Crevel. 2026 DiNardo, Sabiiti, Gillespie, Georghiou, Heinrich, Hittel, Taghlabi, Longlax, Kohli, Panzner, Musia, Lange, Vasiliu, Arts, Mandalakas, Ruhwald, Stuyver and van Crevel https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. A Correction on Inclusion of patient-centered, non-microbiological endpoints and biomarkers in tuberculosis drug trials By DiNardo AR, Sabiiti W, Gillespie SH, Georghiou SB, Heinrich N, Hittel N, Taghlabi S, Carrero Longlax D, Kohli M, Panzner U, Musia C, Lange C, Vasiliu A, Arts RJW, Mandalakas AM, Ruhwald M, Stuyver LJ and van Crevel R (2025) Front. Antibiot. 4:1570989. doi: 10.3389/frabi.2025.1570989 tuberculosis biomarker cardiovascular sequelae cancer Deutsches Zentrum für Infektionsforschung 10.13039/100009139 section-at-acceptance Antibiotics in Clinical Settings

An incorrect Funding statement was provided. The correct Funding statement reads:

“This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101007873. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA, Deutsches Zentrum für Infektionsforschung e. V. (DZIF), and Ludwig-Maximilians-Universität München (LMU). EFPIA/AP contribute to 50% of funding, whereas the contribution of DZIF and the LMU University Hospital Munich has been granted by the German Federal Ministry of Education and Research”.

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland